• 3D bone marrow niche model recapitulates in vivo interactions of tumor and bone cells in a more biologically relevant system than in 2D.
Introduction
Increasing evidence demonstrates that matrix stiffness, geometry, chemistry, and spatial dimensionality, along with neighboring cells and soluble factors, regulate cellular behavior and tissue formation. 1 However, current in vitro multiple myeloma (MM) research is conducted on 2D in vitro culture plates, highlighting the need for more realistic 3D in vitro models of myeloma growth.
2 Many 3-dimensional (3D) culture and coculture systems have been described for MM and have validated the importance and relevancy of using 3D rather than 2D culture systems to more accurately model myeloma growth. Some of these models have used hydrogels (made from permutations of collagen, fibronectin, and Matrigel 3, 4 ), which are, as with our model, advantageous as simple, controllable, and reproducible 3D culture microenvironments useful for studying pharmaceuticals or biological pathways. However, our system transcends these properties to comprise a model representative of a mineralized bone microenvironment using bone marrow (BM)-derived mesenchymal stromal cells (MSCs) that are stimulated to undergo osteogenic differentiation on the strong, porous silk scaffolds, which does not occur on softer substrates. This is a critical component to a 3D model of myeloma and bone, because myeloma cells respond differently to undifferentiated MSCs compared with MSCs differentiated into osteoblasts and osteocytes. 5 On the other end of the spectrum are the models that use 100% biologically relevant patientderived, whole-bone cores, 6 taken directly from patients, which have the advantage of providing a hard, mineralized, bony matrix but that lack the reproducibility, adaptability, scalability, controllability, and simplicity that characterize our tissue-engineered bone (TE-bone) model. Although this is beneficial for small-scale, individualized patient analyses, patient samples vary widely in results and responses in terms of myeloma growth and drug response, making large drug screens or biological pathway analyses impossible. Moreover, the 3D bioreactor system necessary for patient-bone core culture makes the system much more time-and cost-consuming than 3D TE-bone, which can be completely user-defined in terms of size, shape, porosity, and other parameters, and can be produced as hundreds of identical samples. Silk scaffolds, the platform of our TE-bone, can also be modified in terms of pore size, dimensions, Young's modulus, degradation speed, and seeded cellular components. Finally, our TE-bone can be used in vitro or in vivo, monitored using live, nondestructive optical imaging, and processed using flow cytometric techniques for analysis of cellular populations. Herein we use this novel disease model to demonstrate real-time inhibition of osteogenic differentiation in response to myeloma cells.
Osteolytic cancers such as MM develop via forward-feedback mechanisms with local MSCs in the BM, leading to devastating skeletal consequences (ie, pain, hypercalcemia, osteolysis, and fracture) and accelerated tumor growth. 7 MM cells insidiously overtake normal bone homeostasis to decrease osteoblastic activity and increase osteoclastic activity by altering local microenvironment cells. 8 MM patient-derived MSCs (MM-MSCs) exhibit decreased proliferation and osteogenesis and an inability to repair osteolytic damage, and they display great patient-to-patient heterogeneity in their ability to undergo differentiation and induce changes in MM cells. [8] [9] [10] The tumor BM microenvironment also supports tumor growth, 11 induces chemoresistance, and selects for tumor-initiating clones. 12 Therefore, a realistic model of the abnormal BM seen in MM patients would greatly benefit translational research scientists.
In myeloma patients, bone lesions with concomitant bone fractures and osteoporosis often persist despite bisphosphonate or bortezomib administration, tumor cell ablation, or disease remission. 13, 14 This is partially explained by functional and gene expression differences between MM-MSCs and normal donor (ND)-MSCs. 8, [15] [16] [17] [18] However, mechanisms governing ineffectual MM-MSC osteogenesis remain unclear, and the roles of microRNAs (miRs) in this process are unknown. This highlights our need for stroma-specific targets and therapies, which can be identified only with more realistic 3D bone cancer models.
Our 3D in vitro BM model recapitulates interactions among tumor cells, stroma cells (MSCs), and endothelial cells, and the osteogenic process in normal and myeloma conditions. Our purpose was to examine dynamic cell-to-cell interactions between tumor cells and supportive cells, to determine the inhibitory effects of MM cells on osteogenesis and to develop a robust preclinical model to accelerate the rate of discovery and development of efficacious cancer treatments.
Methods

Study approval
Approval for these studies was obtained from the Dana-Farber Cancer Institute or Brigham and Women's Institutional Review Boards. Informed consent was obtained from all patients and healthy volunteers in accordance with the Declaration of Helsinki.
TE-bone
Porous, aqueous 8% (wt/wt) silk fibroin scaffolds were made following the silk processing steps previously described 19 but were specifically designed with pores of 500 to 600 mm and cut into cylinders (5-mm 3 3-mm height). Scaffolds were autoclaved for sterilization and soaked in media containing 10% fetal bovine serum 1 day before seeding. 1 3 10 6 MSCs were seeded onto scaffolds in regular MSC culture media and grown for 1 day, and then changed to osteogenic media. Osteogenic media consisted of a modified Eagle medium (aMEM) supplemented with 10% FBS, 100 U/mL penicillin, 10 mg/mL streptomycin (Invitrogen), 2 mmol/L L-glutamine (Invitrogen), 0.05 mM ascorbic acid, 100 nM dexamethasone, and 10 mM b-glycerophosphate. When cultured with MM1S (or without but used as controls for coculture studies), dexamethasone was excluded from the media.
Cell culture
The human multiple myeloma cell line MM1S was purchased from ATCC (American Type Culture Collection), engineered to express green fluorescent protein (GFP) and firefly luciferase (Luc 1 /GFP 1 MM1S cells) as previously described, 20 and was cultured in 500 mg/mL geneticin (Invitrogen) for selection. OPM2 MM cells were labeled with red fluorescent protein (RFP) and firefly luciferase and provided by Dr Andrew Kung, Columbia University. Primary human BM-derived MSCs obtained from normal healthy subjects (ND-MSCs) or MM patients (MM-MSCs) were isolated and cultured as previously described 21 in expansion media of Dulbecco's modified Eagle medium (DMEM)120% FBS and used at passages 2 to 4. Clinical samples were collected from patients or healthy donors from the Dana-Farber Cancer Institute and Brigham and Women's Hospital. Primary patient samples were isolated from MM patient BM aspirates using MACS technology (Miltenyi Biotec) with beads for CD138 as recommended by the manufacturer, and the negative fraction was seeded to flasks and grown as previously described to isolate BM-MSCs. 21 For imaging assays, MSCs were labeled with either the Celltracker dye DiD (Invitrogen) or calcein for live-cell imaging (Invitrogen), or they were stably transfected with the TurboRFP gene (Thermo Scientific) subcloned into pCW307 lentivirus vector (Addgene). Primary patient myeloma cells and MSCs were cocultured in "50-50" medium: a base of 50-50 F12-DMEM (Invitrogen) supplemented with 10% FBS, 100 U/mL penicillin, 10 mg/mL streptomycin (Invitrogen), and 2 mmol/L L-glutamine (Invitrogen). RFP-labeled HUVECS (RFP-HUVECS) were purchased from Angioproteomie and expanded in Endothelial Medium (EGM-2 BulletKit media; Lonza). All experiments were performed at 37°C, 5% CO 2 in normoxia.
3D scaffold coculture
Fluorescent (TurboRFP or DiD 1 ) MSCs were seeded onto scaffolds as described. 19 For personal use only. on April 20, 2017 . by guest www.bloodjournal.org From images were acquired and processed using LeicaLite or LeicaLAS software to create single maximum projection 3D-like images or videos. Nonconfocal fluorescent microscopy was performed using an Olympus CKX41 microscope with appropriate filter cubes and an Olympus DP72 Camera and dry 310 or 320 objectives. 
Bioluminescence imaging quantification
Scanning electron microscopy and micro-computed tomography
Scanning electron microscopy images of scaffolds were taken on a Nikon Eclipse 80i microscope with a DSFi1 Nikon Color Camera with NIS Elements AR Software. Scanning electron microscopy was done using a JEOL scanning electron microscope with gold sputter coating on scaffolds after fixation in 4% PFA. Microcomputed tomography (mCT) imaging was performed on scaffolds fixed overnight in 4% PFA and transferred to 70% ethanol in 1.5 mL Eppendorf tubes on a Siemens Inveon multimodality machine (positron emission tomography-single-photon emission tomographymCT) at the Dana-Farber Cancer Institute Lurie Imaging Facility Core.
Cell counting
MM-MSCs (n 5 4 donors) and ND-MSCs (n 5 4 donors) were seeded to 12-well plates (5000 stromal cells/cm 2 ) with or without GFP 1 MM1S
(1250 MM1S cells/cm 2 ) and cultured for 9 days in 50-50 culture media. Cells were then fixed and stained with a 10% neutral-buffered formalin, 1 mg/mL Hoechst (Invitrogen) solution for 10 minutes, and photographed (at least 3 representative fields of view/well) using brightfield and fluorescent (UV filter) microscopy with a Nikon Eclipse 80i microscope (203), a DSFi1 Nikon Color Camera, and an NIS Elements AR Software, and then counted by a blinded investigator using the ImageJ Cell Counter plugin (v1.47). The mean number of cells/cm 2 6 standard error of the mean (SEM) was calculated and graphed.
Matrigel and fibrin-hydrogel culture
Fibrinogen (Sigma-Aldrich) and thrombin (human BioUltra recombinant, Sigma-Aldrich) were mixed to create 4-mg/mL fibrin hydrogels. Matrigel (BD Biosciences) was diluted 1:3 in phosphate-buffered saline. Both hydrogels were immediately mixed with cells (cell tracker dye DiR mRNA and miR isolation and qRT-PCR miRNAs and mRNAs were isolated from cells using the miRNeasy isolation mini-kit (Qiagen), quantified, and tested for quality and contamination using a Nanodrop machine (ThermoScientific), 21 and then subjected to quality . For miRNA expression analysis of the 3D model system, 5 normal stroma cultured alone or in coculture with MM1S myeloma cells, isolated by FACS after 2 weeks of coculture, were analyzed and compared with clinical samples, (3 ND-MSC and 7 MM-MSC samples analyzed at passage 2). Primary samples (normal donor or myeloma patient) and 3D model samples (coculture vs alone) were both analyzed for stromal cell expression of 800 miRNAs using the nanoString miR analysis platform (nCounter human miRNA Expression Assay) following the manufacturer's protocol. Briefly, default settings for quality control on miR samples were used to assure high-quality miR and accuracy of the experimental process for 4 parameters (imaging, binding density, positive control linearity, and control limit of detection). A total of 100 ng of mRNA and miR was used as input into the sample preparation reaction for the nanoString nCounter assay. The miRNAs were all then normalized to the top 100 miRs per sample (by averaging the expression of the top 100 miR per sample, and then dividing all miR by this number), filtered for miRs with an average of .25 counts (cutoff in nanoString units of expression to establish real expression) and considered significant for P , .05 using dChip software analysis, following the manufacturer's instructions and previously reported literature. 22 An abundance of specific target molecules was quantified robotically on the nCounter Digital Analyzer by counting the individual fluorescent barcodes and assessing the target molecules on the sample cartridge with a charge-coupled device camera as reported previously. 22 For each assay, a high-density scan setting encompassing 600 fields of view was used. miRs reaching a minimum threshold of 25 counts, fc of .1.5, and significance of P , .05 were identified as significant and were further investigated in miR mimic assays.
miR transfection
MM-MSCs were transfected with miR-199a-3p and miR-199a-5p miR mirVana mimics (Ambion) and a negative control (mirVana negative control mimic #1) or miRCURY (Exiqon) inhibitors for miR-181a-5p, miR181c-5p, miR-222-3p, miR-601, miR-146a-5p, and miRCURY negative control, following the manufacturer's instructions. MSCs were cultured until they were 80% confluent and were then transfected with a final concentration of 30 nM of each miR mimic or 50 nM of each miRCURY Inhibitor for 24 hours using Lipofectamine 2000 (Invitrogen). Alizarin Red Solution staining and qRT-PCR were performed on samples after 10 days of culture in osteogenic (dexamethasone-free) media. Efficiency of transfection was validated by qRT-PCR for detection of miR levels at 24 hours and 10 days as previously described. 21 
Pathway enrichment analysis
The targets of miR-199a-5p were predicted by TargetScan 23 and retrieved from online (http://www.targetscan.org/). We used pathways derived from 3 databases-BioCarta, KEGG, and Reactome-which were downloaded from MSigDB. 24 Hypergeometric testing was used to assess the enrichment of pathways. The enrichment P values were adjusted to account for multiple testing, resulting in a false discovery rate for each pathway, 25 and pathways were identified using a false discovery rate cutoff of 10%.
Statistics
Statistical analysis was performed using GraphPad/Prism Version 6.02 or Microsoft Excel. P values are based on Student's t tests (2-tailed) for 2-way comparisons, or analysis of variance (ANOVA) for multiple hypothesis testing using post hoc Dunnett (2-way ANOVA) or Fisher least significant difference (LSD) (1-way ANOVA) multiple comparison testing. Sample variance was determined using an F-Test, and normality was determined using a Normal Quantile Plot to test for non-normality (Q-Q probability plot). P , .05 was considered significant and P values are provided in the figures or their captions. Statistics for heat maps were done using dChip software using P , .05 as significant.
Results
We first developed our TE-bone model and characterized its unique ability to represent a mineralized 3D bone matrix, not afforded by any previously described model. Silk scaffolds, which recapitulate the high-compressive strength and porous nature of the BM trabecula, 26 were seeded with ND-MSCs and differentiated into TE-bone using osteogenic media for 50 days. The TE-bone samples formed dense, calcified tissue, as demonstrated by mCT imaging (supplemental Figure 1A ), scanning electron microscopy (supplemental Figure 1B) , and nondestructive fluorescence confocal microscopy ( Figure 1A) . This 3D mineralized model served as a basis to begin studying osteogenesis in the context of myeloma.
Next we tested the ability of myeloma cells to grow in osteogenic media, which would be required in coculture. However, we found dexamethasone to be toxic to both MM1S and OPM2 cells (data not shown) and hence adapted the osteogenic media for our purposes by removing dexamethasone, an alteration that has been previously described. 27 We next tested the ability for OPM2 and MM1S cell lines to grow on the silk scaffolds and found that, although both cell types were able to adhere to ND-MSCs seeded on scaffolds, only MM1S could adhere to the silk scaffolds alone, as observed in confocal imaging (data not shown). Hence for subsequent studies we chose to use MM1S as the main myeloma cell line for this model.
We hypothesized that silk scaffolds would provide a more realistic platform to investigate endothelial cell-myeloma cell interactions in the bone marrow, so we compared coculture responses of these cells in 3D silk scaffolds and hydrogels. We cocultured fluorescent endothelial cells (RFP 1 HUVECs) with GFP 1 MM1S cells and observed cell-to-cell contact and interaction, as well as interesting assembly patterns unique to silk scaffold culture ( Figure 1B , supplemental Figure 2A , and supplemental Video 1 Figure 2B ), supporting validation that the stiffer scaffold substrate more accurately recapitulates the in vivo conditions than do softer substrates. The 3D silk scaffold model also recapitulated the ability for MSCs to protect GFP 1 MM1S cells from therapeutic agents such as bortezomib over a 30-day treatment period, as quantified with bioluminescent imaging (supplemental Figure 3A) and imaged with confocal microscopy ( Figure 1C ). This was not achieved in 2D culture (supplemental Figure 3B) , defining the 3D system as a unique environment suitable for long-term drug studies. Similarly, in vitro growth of primary MM tumor cells in 2D lacks the realistic complexity of a 3D milieu, explaining why primary patient MM cell growth was observed on MSC-seeded scaffolds over 11 days but was not possible under the same conditions in 2D culture. 28 Primary MM cells were labeled with cell-tracker dyes and imaged with confocal microscopy using calcein to assess cell viability ( Figure 1D and supplemental Figures 4 and 5 ). They were further identified with H&E and human-CD138 stains on fixed scaffold samples to ensure plasma cell identity (supplemental Figure 6) . Together, these findings indicate that our 3D BM model allows for cancer-bone modeling in a more biologically relevant system than does 2D culture or soft 3D culture.
To address the study of myeloma-induced osteogenesis inhibition, we first confirmed prior reports 8 that proliferation and osteogenesis are significantly inhibited by myeloma in clinical samples (MM-MSCs vs ND-MSCs) and in vitro 2D cocultures of ND-MSCs and myeloma cells (supplemental Figures 7 and 8) . We also assessed the mRNA profile of clinical samples (ND-MSCs and MM-MSCs) by analyzing 230 mRNAs involved in cell proliferation, differentiation, migration, and other vital signaling. Unsupervised analysis demonstrated distinct clustering between ND-MSCs and MM-MSCs, confirming inherent differences between normal and myeloma stroma (supplemental Figure 9A) . Forty-nine mRNAs were found to have significantly different expression between ND-MSCs and MM-MSCs (P , .05, 1.5-fc; supplemental Figure 9B ), including the cell-cycle regulators CDKN2A (p16, previously reported 29 ) and CDKN1A (p21, not previously reported), which may contribute to the decreased MM-MSC proliferation, and Collage1A1, likely contributing to decreased bone matrix formation.
We then attempted to model inhibited osteogenesis of MSCs in our 3D BM model. ND-MSCs and GFP 1 MM1S were cultured alone or together on scaffolds in osteogenic media over 5 weeks. Confocal and fluorescent microscopy showed that GFP 1 MM1S cells inhibited ND-MSC proliferation, migration, and tissue production in scaffolds ( Figure 2A- For personal use only. on April 20, 2017 . by guest www.bloodjournal.org From demonstrated cellular tissue formation and mineralization in ND-MSC samples grown alone. Conversely, a lack of mineralization, as well as poor tissue formation and decreased cell numbers, were observed in samples of ND-MSCs cocultured with MM1S cells ( Figure 2C) . Interestingly, by week 2 the inhibition of MSC growth was evident in confocal imaging, and this trend continued over the full 5-week period, whereas MSCs alone proliferated, filled in scaffold pores, and formed mineralized, TE-bone. In sum, this system is useful for investigating myeloma effects on 3D osteogenesis in a more realistic setting than in 2D.
We then investigated the role of miRs in the dysfunctional osteogenesis of MSCs cultured with myeloma cells. TurboRFP 1 ND-MSCs were cultured alone or with GFP 1 MM1S cells in the 3D model in osteogenic media for 2 weeks, sorted and collected using FACS, and analyzed for miR changes (coculture vs monoculture) using nanoString analysis of 800 miRs. Fifty-three miRs (28 up-and 25 downregulated) showed significantly altered expression in MSCs during coculture with MM1S ( Figure 3A and supplemental Table 2 ).
To compare with clinical samples, miR profiling was also performed on BM stroma samples from normal, healthy donor or myeloma patients. These samples demonstrated 41 miRs (34 up-and 7 downregulated) with significantly altered expression in MSCs from myeloma patient donors (MM) vs normal donor MSCs (ND) ( Figure 3B and supplemental Table 2 ). Of these, six were found to be similarly downregulated (1 miR) or upregulated (5 miRs) in the 3D coculture system in the 3D model compared with the clinical samples ( Table 1) . The correlation between the patient and normal samples, and the BM niche 3D model contributes additional evidence that our system can reliably recapitulate many of the in vivo effects of MM cells on MSCs and suggests miRs that may govern the inhibited osteogenesis seen in patient MSCs. All miR data can be found in the GEO database under accession number GSE60423. Finally, we examined whether any of the 6 miRs identified in the 3D model and in the clinical samples could serve as targets for inducing osteogenesis. Inhibition of miRs overexpressed in MM-MSCs (miR-181a-5p, miR181c-5p, miR-222-3p, miR-601, miR-146a-5p) using miRCURY inhibitors did not alter the mineralization potential of MM-MSCs as assessed by Alizarin Red Solution (data not shown) and hence were not further pursued. However, increasing the expression of miR-199a-5p significantly increased mineralized matrix production, indicative of osteogenic potential, and further supported the function of miR-199a as an osteogenic-promoting miR ( Figure 3C-D) . Using miR mimic transfection in ND-MSCs and MM-MSCs, we increased expression of miR-199a and observed that increasing the expression of both miR-199a-5p and miR-199a-3p in MM-MSCs significantly increased expression of several common osteogenic markers previously described, 30 namely, alkaline phosphatase, integrin-binding sialoprotein, collagen type I a 1, osteopontin, osteocalcin, and runt-related transcription factor 2 ( Figure 3E -F and supplemental Figure 10 ). Similar results were found with transfection of ND-MSCs with miR-199a-3p and 199a-5p mimics (data not shown).
To explore the potential pathways regulated by hsa-miR-199a-5p, we performed a pathway enrichment analysis of its predicted target genes. Analysis of miR-199a-5p targets revealed 19 pathways that were significantly enriched (supplemental Table 3 ). Interestingly, among them the ErbB signaling pathway was identified and is also reported to be involved in osteogenesis. 31, 32 The MAPK signaling pathway was also identified by us, as well as by others, 33 as an miR199a-5p target pathway, and has been shown to play a role in osteogenic differentiation via the ErbB1 and ErbB2 pathways. 34 Moreover, 3 pathways centered on semaphorins were also identified For personal use only. on April 20, 2017 . by guest www.bloodjournal.org From and may play a role in osteogenesis formation, 35, 36 although this is currently not well-defined. 37 Hence, the pathways identified here may explain the mechanisms by which miR199a-5p regulates mRNAs that have anti-osteogenic effects (such as semaphorin4D) and may suggest novel pathways that could be targeted to normalize the osteogenic differentiation of MM-MSCs.
Discussion
3D culture models with material properties similar to those found in vivo are materializing as essential tools in cancer biology, owing to their ability to replicate tissue-or organ-specific structural features, biomechanical properties, and cell-cell or cell-extracellular matrix interactions more accurately than conventional 2D culture. Our new preclinical bone cancer model has the capacity to support long-term culture and imaging for expansion of primary myeloma cells, highthroughput drug screening, vessel formation, and osteogenesis in the presence of cancer. Prior published models have used soft, hydrogel matrices that cannot be mineralized and therefore cannot mimic the bone microenvironment. 3, 4 Our 3D model uses silk protein-based scaffolds that allow for active cell attachment and adherence to scaffolds rather than passive encapsulation in 3D hydrogel cultures. In addition, the tissue-engineering approach represents a more controllable model compared with culturing whole-patient bone biopsies, 6 because it allows for user-designed introduction of cells of interest, increasing the reproducibility, adaptability, and scalability of the model. Therefore, the silk-based 3D TE-bone model presented herein represents a unique model to examine the interactions of bone and cancer cells in a 3D microenvironment, with mechanical properties similar to bone.
It remains to be determined why a decrease in certain miRs may lead to inhibited osteogenesis in myeloma and what mRNA targets drive this, but it is evident that overexpressing certain miRs within MSCs can increase their osteogenic potential, and our 3D model helped to identify 199a-5p as one such miR. MiR-199a has been described as "flexible and versatile as a chameleon,"
33 because it has a wide variety of important functions across many cell types and systems. In terms of osteogenesis, miR-199a-5p specifically has been shown to have a pro-stem cell differentiation effect in BM-derived human MSCs both in vitro and in vivo, whereas inhibition with siRNAs blocking miR-199a-5p reduced osteogenesis of hMSCs. 38, 39 Pathways implicated in this are still uncertain but include HIF1a, TWIST, NADPH-oxidase, PI-3 kinase, mitogen-activated protein kinase, and NF-kB pathways, which are being investigated for their roles in osteogenesis. 38, 40 miR-199a is also a BMP2-responsive miR, 41 suggesting that altered BMP2 signaling may be involved in the observed effects of these miRs. Decreased 199a-5p may also increase fibronectin in MM BM, which is elevated in MM patient serum 42, 43 and has been shown to cause increased MM tumor accumulation within the BM and dictate CAM-DR. 44 Although the exact composition and interaction of mRNAs inhibited by miR-199a appear to be complex, it is clear that miR-199a represents the first miR identified as abnormally downregulated, and one of the first abnormally expressed 45 in bone cancer patients, that may be a therapeutic strategy for enhancing bone formation.
The roles of specific miRs in osteogenesis and MSC-tumor feedback are currently enigmatic, 39 ,46 but our results suggest that novel target miRs are useful for reactivating the osteogenic abilities of cancer-associated MSCs. Targeting these miRs may provide a new avenue for healing lesions and reversing the osteolytic cancer cycle in myeloma along with other osteotropic cancers. In conclusion, the novel 3D, in vitro bone cancer model developed provides a physiologically relevant platform to investigate osteogenesis, angiogenesis, and cancer growth, as well as drug response with primary samples and cell lines. It allows for nondestructive imaging over long periods and can be used for testing a multitude of other bone cancer hypotheses and modeling an array of biological processes involved in the inhibited osteogenesis of cancer-colonized bones. More broadly, many researchers would likely increase their in vivo success rates by first testing their hypotheses in our 3D model system. Our For personal use only. on April 20, 2017 . by guest www.bloodjournal.org From model allows biological questions to be investigated, compounds to be screened, and novel targets or therapeutics to be identified more quickly and cheaply and in a more realistic 3D BM niche setting than is currently available. Resulting research will be more clinically translatable and will advance more quickly and efficiently from the bench to the bedside of patients who have bone cancer. For personal use only. on April 20, 2017 . by guest www.bloodjournal.org From
